00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
00:19 , Jan 3, 2019 |  BC Extra  |  Company News

Management tracks: Portola, Coherus

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said SVP and CMO John Lawrence has resigned to pursue a new position with an undisclosed pharma company. Coherus BioSciences Inc. (NASDAQ:CHRS) hired Darlene Horton as chief medical and...
00:06 , Dec 20, 2018 |  BC Extra  |  Company News

Management tracks: Prometic, Synlogic

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) board member and CEO Pierre Laurin stepped down to pursue other opportunities. Chairman Simon Best was named interim CEO while the fibrosis and orphan disease company searches for a...
22:09 , Dec 17, 2018 |  BC Extra  |  Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
17:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

Michigan to begin talks with drug manufacturers for value-based deals

With a stamp of approval from CMS on Nov. 14, Michigan joins Oklahoma as one of the only two states with the agency's OK to negotiate Medicaid outcomes-based pricing agreements with drug manufacturers. "Michigan’s waiver...
23:55 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Michigan to begin talks with drug manufacturers for value-based deals

With a stamp of approval from CMS on Wednesday, Michigan joins Oklahoma as one of the only two states with the agency's OK to negotiate Medicaid outcomes-based pricing agreements with drug manufacturers. "Michigan’s waiver will...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
17:03 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
15:56 , Oct 26, 2018 |  BioCentury  |  Finance

Rempex remix

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio....